Kangtai bio begins phase 1 trial for quadrivalent flu vaccine

Shenzhen Kangtai Biological Products Co., Ltd. (Kangtai Bio) has announced the commencement of Phase 1 clinical trials for its quadrivalent influenza virus split vaccine, designed for individuals aged 6 to 35 months. The company successfully enrolled its first subject, indicating the completion of trial preparations. This vaccine aims to stimulate immunity against influenza viruses and prevent influenza caused by vaccine-related strains.

The Phase 1 trial is a single-center, randomized, blind, positive-controlled study, evaluating the safety and preliminary immunogenicity of the vaccine in the target age group. The company believes that successful development will enhance its product portfolio, core competitiveness, and market position.

Kangtai Bio cautions that vaccine development is a complex and lengthy process. The company will proceed according to regulatory requirements, but the progress and outcomes of subsequent clinical trials, as well as the timeline for production approval and market launch, remain uncertain. Investors are advised to exercise caution due to these inherent risks.